Hemin

DB03404ApprovedInvestigationalProtein Based Therapies

Hemin is an iron-containing porphyrin injection used for the relief of recurrent attacks of acute intermittent porphyria (AIP) associated with the menstrual cycle when carbohydrate therapy is not effective. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.

Mechanism
Curator reviewed
Primary indication
Used in the management of porphyria attacks, particularly in acute intermittent porphyria.Curator reviewed · 3 structured indications
First approval
Canada, 2018 · United States, 1983
Also known as
chloro(protoporphyrinato)iron(III) · protohemin
Brand names
  • Panhematin

Resolves to

Compound
UNII743LRP9S7NCAS16009-13-5ChEBI50385KEGGC06767
Clinical / RWD
RxNorm5175ATCB06AB01
Targets
P13196ALAS1

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
82Drug interactionsStructured to mechanism, not free text
Sign in
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
9Marketed productsAcross 5 countries and 5 labellers
Sign in
1ATC codeIncluding every combination product, plus 8 drug categories
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Hemin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In